TJHA
ALXN

Thomas J. Herzfeld Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Thomas J. Herzfeld Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-88
Closed -$12K – 338
2017
Q3 		$12K Sell
88
-46
-34% -$6.25K 0.01% 239
2017
Q2 		$16K Sell
134
-18
-12% -$2.1K 0.01% 227
2017
Q1 		$18K Hold
152
– – 0.01% 274
2016
Q4 		$19K Buy
152
+54
+55% +$6.61K 0.01% 284
2016
Q3 		$12K Sell
98
-30
-23% -$3.86K 0.01% 274
2016
Q2 		$15K Hold
128
– – 0.01% 287
2016
Q1 		$18K Sell
128
-10
-7% -$1.47K 0.01% 304
2015
Q4 		$26K Hold
138
– – 0.01% 262
2015
Q3 		$22K Buy
138
+15
+12% +$2.74K 0.01% 275
2015
Q2 		$22K Buy
+123
New +$21.2K 0.01% 245

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Thomas J. Herzfeld Advisors's ALXN Position: Q4 2017 in Review

Thomas J. Herzfeld Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q4 2017, closing a stake of 88 shares — an estimated $12K sold.

Thomas J. Herzfeld Advisors first reported a position in ALXN in Q2 2015 and held it in 10 quarters. The position peaked at $26K in Q4 2015. 587 funds tracked by Wall St. Rank hold ALXN as of Q4 2017.

  • Thomas J. Herzfeld Advisors reported no remaining Alexion Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Thomas J. Herzfeld Advisors sold 88 Alexion Pharmaceuticals shares in Q4 2017, an estimated $12K.
  • Thomas J. Herzfeld Advisors first reported a position in Alexion Pharmaceuticals in Q2 2015 and held it in 10 quarters.
  • Thomas J. Herzfeld Advisors's Alexion Pharmaceuticals position peaked at $26K in Q4 2015.
  • 587 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2017.

Based on Thomas J. Herzfeld Advisors's 13F filing for Q4 2017, filed 14 Feb 2018.